Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 13, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 2, 2026Reported sale · Form 4Timothy Schmid, EVP, WW Chair, MedTech · $3.0MOpen the filing ↗
- Sep 2, 2026Reported sale · Form 4Timothy Schmid, EVP, WW Chair, MedTech · $6.2MOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,7733 flagged findings
Reported transactions (Form 4)80since Feb 17, 2026 · and 40 other holdings
Corporate events (8-K)30since Apr 17, 2018
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
The 25 most recent filings (of 2,773)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 13, 268-K ↗Current report · Results new
- Sep 2, 26Form 144 ↗Notice of proposed sale
- Sep 1, 26Form 3 ↗Insider transaction
- Aug 18, 26Form 4 ↗Insider transaction
- Aug 17, 26Form 144 ↗Notice of proposed sale
- Aug 14, 26Form 4 ↗Insider transaction
- Aug 13, 26Form 144 ↗Notice of proposed sale
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Aug 6, 26Form 144 ↗Notice of proposed sale
- Aug 5, 26Form 144 ↗Notice of proposed sale
- Aug 4, 268-K ↗Current report · A senior executive left or was appointed
- Jul 29, 268-K ↗Current report · Communication to the market
- Jul 28, 268-K ↗Current report · Communication to the market
- Jul 23, 2610-Q ↗Quarterly report
- Jul 21, 26Form 4 ↗Insider transaction
- Jul 20, 26Form 144 ↗Notice of proposed sale
- Jul 15, 268-K ↗Current report · Results
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 11, 26Form 144 ↗Notice of proposed sale
- Jun 11, 26Form 4 ↗Insider transaction
2,773 filings on record, the oldest from Apr 1, 94.
Listing the 25 most recent filings of the 2,773 on record.
42346
9 senior executive changes2023 – 2026show all 9hide
- Aug 4, 26A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 9, 25A senior executive left or was appointed8-K 5.02 ↗
- Jun 10, 25A senior executive left or was appointed8-K 5.02 ↗
- Apr 30, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 10, 24A senior executive left or was appointed8-K 5.02 ↗
- Aug 26, 24A senior executive left or was appointed8-K 5.02 ↗
- Dec 5, 23A senior executive left or was appointed8-K 5.02 ↗
- Nov 27, 23A senior executive left or was appointed8-K 5.02 ↗
- Oct 23, 23A senior executive left or was appointed8-K 5.02 ↗
- Aug 25, 23Completed an acquisition or disposal8-K 2.01 ↗
- May 8, 23Entered a material agreement+1 more in the same filing8-K 1.01 ↗
4 senior executive changes2023show all 4hide
- May 1, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 3, 23A senior executive left or was appointed8-K 5.02 ↗
- Feb 15, 23A senior executive left or was appointed8-K/A 5.02 ↗
- Feb 14, 23A senior executive left or was appointed8-K 5.02 ↗
- Dec 22, 22Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Dec 1, 22A senior executive left or was appointed8-K 5.02 ↗
- Nov 1, 22Entered a material agreement+2 more in the same filing8-K 1.01 ↗
8 senior executive changes2019 – 2022show all 8hide
- Apr 29, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 16, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 6, 22A senior executive left or was appointed8-K 5.02 ↗
- Oct 12, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Aug 20, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 3, 20A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Dec 5, 19A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Oct 7, 19A senior executive left or was appointed8-K 5.02 ↗
- Apr 1, 19A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Jun 22, 18A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 17, 18Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
The record reaches back to Dec 8, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Jan 19, 16Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
- Nov 30, 07Write-down of assets+1 more in the same filing8-K/A 2.06 ↗
- Nov 29, 07Write-down of assets+1 more in the same filing8-K 2.06 ↗
The full record holds 4 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- The Vanguard Group10.1%Jan 30, 26SCHEDULE 13G/A ↗
- Vanguard Capital Management7.5%Mar 31, 26SCHEDULE 13G ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 2, Schmid Timothy filed notice of intent to sell up to $9.2M.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $9.2M across 2 trades on Sep 2, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+5 more recent notices · 5 with a later sale
- Sep 2, 26Sell$3.0MTimothy SchmidEVP, WW Chair, MedTech↗
- Sep 2, 26Sell$6.2MTimothy SchmidEVP, WW Chair, MedTech↗
- Aug 17, 26Sell$4.0MJennifer L TaubertEVP, WWC. Innovative Medicine↗
- Aug 13, 26Sell$5.5MJoaquin DuatoCEO and Chairman of the Board↗
- Aug 13, 26Sell$26.7MJoaquin DuatoCEO and Chairman of the Board↗
- Aug 6, 26Sell$2.4MElizabeth ForminardEVP, Chief Legal Officer↗
- Aug 6, 26Sell$1.7MElizabeth ForminardEVP, Chief Legal Officer↗
- Aug 5, 26Sell$10.8MJoaquin DuatoCEO and Chairman of the Board↗
- Aug 5, 26Sell$1.7MJoaquin DuatoCEO and Chairman of the Board↗
- Jul 20, 26Sell$5.8MVanessa BroadhurstEVP, Global Corp Affairs↗
- Jun 11, 26Sell$2.4MKathryn E WengelEVP, Chief TO and Risk Officer↗
- Feb 27, 26Sell$1.0MRobert J DeckerVP Corporate Controller↗
There are 10 more transactions in this stretch.
Stock compensation, tax and giftsshow the 18 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 2, 26Compensation$1.5MTimothy SchmidEVP, WW Chair, MedTech↗
- Sep 2, 26Compensation$3.4MTimothy SchmidEVP, WW Chair, MedTech↗
- Aug 17, 26Compensation$1.7MJennifer L TaubertEVP, WWC. Innovative Medicine↗
- Aug 13, 26Compensation$14.3MJoaquin DuatoCEO and Chairman of the Board↗
- Aug 6, 26Compensation$1.2MElizabeth ForminardEVP, Chief Legal Officer↗
- Jul 20, 26Compensation$1.4MVanessa BroadhurstEVP, Global Corp Affairs↗
- Jul 20, 26Compensation$1.6MVanessa BroadhurstEVP, Global Corp Affairs↗
- Jun 11, 26Compensation$1.2MKathryn E WengelEVP, Chief TO and Risk Officer↗
- May 1, 26Compensationamount n/aJOHN C REEDEVP, Innovative Medicine, R&D↗
- May 1, 26Tax$2.5MJOHN C REEDEVP, Innovative Medicine, R&D↗
- Feb 27, 26Compensation$471KRobert J DeckerVP Corporate Controller↗
- Feb 18, 26Compensation$1.6MTimothy SchmidEVP, WW Chair, MedTech↗
- Feb 18, 26Compensation$1.2MTimothy SchmidEVP, WW Chair, MedTech↗
- Feb 17, 26Compensation$3.4MJOHN C REEDEVP, Innovative Medicine, R&D↗
- Feb 17, 26Compensation$4.7MJOHN C REEDEVP, Innovative Medicine, R&D↗
- Feb 17, 26Compensation$2.2MJoseph J WolkExec VP, CFO↗
- Feb 17, 26Compensation$1.6MJoseph J WolkExec VP, CFO↗
- Feb 17, 26Compensation$4.4MJoseph J WolkExec VP, CFO↗
The full record holds 408 transactions and goes back to Jan 3, 22.
Its sector and its market
Johnson & Johnson among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Johnson & Johnson, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Johnson & Johnson in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,773 documents on file, from Apr 1, 1994 to Oct 13, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.